Hepatitis Delta Infection: A Clinical Review
Seminars in Liver Disease · 01.08.2023 · 43 (03) · 293-304
DOI: 10.1055/a-2133-8614 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, erschienen am 01.08.2023. Verfasst von Brian Pearlman. Beteiligte Einrichtung: Department of Internal Medicine, Wellstar Atlanta Medical Center, Medical College of Georgia, Emory School of Medicine, Atlanta, Georgia. Hauptthemen laut MEDLINE: Hepatitis B, Coinfection, Liver Neoplasms, Hepatitis D. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
First discovered over 40 years ago, the hepatitis delta virus (HDV) is a unique RNA virus, requiring hepatitis B virus (HBV) antigens for its assembly, replication, and transmission. HBV and HDV can be acquired at the same time (coinfection) or HDV infection can occur in persons with chronic HBV (superinfection). Screening guidelines for HDV are inconsistent. While some guidelines recommend universal screening for all people with HBV, others recommend risk-based screening. Estimates of the global HDV prevalence range from 4.5 to 14.6% among persons with HBV; thus, there may be up to 72 million individuals with HDV worldwide. HDV is the most severe form of viral hepatitis. Compared to HBV monoinfection, HDV coinfection increases the risk of cirrhosis, hepatocellular carcinoma, hepatic decompensation, mortality, and necessity for liver transplant. Despite the severity of HDV, there are few treatment options. Pegylated interferon (off-label use) has long been the only available treatment, although bulevirtide is conditionally approved in some European countries. There are many potential treatments in development, but as yet, there are few effective and safe therapies for HDV infection. In conclusion, given the severity of HDV disease and the paucity of treatments, there is a great unmet need for HDV therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Internal Medicine, Wellstar Atlanta Medical Center, Medical College of Georgia, Emory School of Medicine, Atlanta, Georgia.
Zitieren
APA
Pearlman, B. (2023). Hepatitis Delta Infection: A Clinical Review. Seminars in Liver Disease, 43(03), 293-304. https://doi.org/10.1055/a-2133-8614
Vancouver
Pearlman B. Hepatitis Delta Infection: A Clinical Review. Seminars in Liver Disease. 2023;43(03):293-304. doi:10.1055/a-2133-8614
BibTeX
@article{Pearlman2023,
author = {Pearlman, Brian},
title = {Hepatitis Delta Infection: A Clinical Review},
journal = {Seminars in Liver Disease},
year = {2023},
volume = {43},
number = {03},
pages = {293--304},
doi = {10.1055/a-2133-8614}
}
EUVIMED